MCID: SMT006
MIFTS: 55

Somatoform Disorder

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Somatoform Disorder

MalaCards integrated aliases for Somatoform Disorder:

Name: Somatoform Disorder 12 15 73
Physiological Malfunction Arising from Mental Factor 12
Psychophysiologic Disorders 73
Psychosomatic Disorder 12

Classifications:



Summaries for Somatoform Disorder

Disease Ontology : 12 A disease of mental health that involves physical symptoms suggesting a physical illness where the biological or medical cause of the symptoms is indeterminate.

MalaCards based summary : Somatoform Disorder, also known as physiological malfunction arising from mental factor, is related to chronic pain and gastrointestinal system disease, and has symptoms including dyspnea, headache and meningism. An important gene associated with Somatoform Disorder is TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1), and among its related pathways/superpathways are Regulation of IFNA signaling and Neuroscience. The drugs Pregabalin and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include prostate, brain and cortex, and related phenotypes are homeostasis/metabolism and cardiovascular system

Related Diseases for Somatoform Disorder

Diseases related to Somatoform Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 130)
# Related Disease Score Top Affiliating Genes
1 chronic pain 30.9 COMT OPRM1
2 gastrointestinal system disease 30.5 IL1B TPH1 TRPV1
3 post-traumatic stress disorder 30.3 COMT FAAH IL1B
4 irritable bowel syndrome 30.1 TAC1 TPH1 TRPV1
5 complex regional pain syndrome 29.8 IL1B SCN9A TAC1
6 cystitis 29.4 NGF TAC1 TRPV1
7 interstitial cystitis 29.0 IL4 NGF TAC1 TRPV1
8 paine syndrome 28.5 CABIN1 IL1B NGF SCN9A TAC1 TRPA1
9 somatization disorder 11.9
10 hypochondriasis 11.4
11 conversion disorder 11.2
12 psychogenic movement 11.2
13 body dysmorphic disorder 11.2
14 dissociative seizures 10.8
15 chronic follicular conjunctivitis 10.8 IL1A IL1B
16 diversion colitis 10.7 IL1B IL4
17 anxiety 10.7
18 hyperlucent lung 10.7 IL2RA IL4
19 pulpitis 10.6 IL1A IL1B TRPV1
20 vulvar vestibulitis syndrome 10.6 IL1B IL1RN
21 neonatal abstinence syndrome 10.6 COMT OPRM1
22 hypersensitivity reaction disease 10.6 IL1B IL4 TRPV1
23 immune system disease 10.6 IL1B IL4 TRPV1
24 autoimmune encephalitis 10.6 FAAH TRPV1
25 panic disorder 10.5
26 tonsillitis 10.5 IL1A IL1B IL4
27 gastric cancer, hereditary diffuse 10.5 IL1B IL1RN
28 gingivitis 10.5 IL1A IL1B IL4
29 contact dermatitis 10.5 IL1A IL1B IL4
30 congenital hypogammaglobulinemia 10.5 IL1A IL4
31 disease of mental health 10.5 COMT OPRM1 TRPV1
32 aphthous stomatitis 10.5 IL1B IL1RN IL4
33 tobacco addiction 10.5 COMT OPRM1 TPH1
34 polysubstance abuse 10.5 COMT FAAH
35 schnitzler syndrome 10.5 IL1B IL1RN
36 meningococcemia 10.5 IL1A IL1B IL1RN
37 aseptic meningitis 10.5 IL1A IL1B IL1RN
38 root resorption 10.5 IL1A IL1B IL1RN
39 periodontitis 10.5 IL1A IL1B IL4
40 silicosis 10.4 IL1A IL1B IL1RN
41 leishmaniasis 10.4 IL1A IL1B IL4
42 pertussis 10.4 IL1A IL1B OPRM1
43 cerebral artery occlusion 10.4 IL1B IL1RN
44 osteomyelitis 10.4 IL1A IL1B IL1RN
45 paroxysmal extreme pain disorder 10.4 SCN9A TRPV1
46 interstitial lung disease 10.4 IL1A IL1B IL4
47 lesion of sciatic nerve 10.4 NGF TRPV1
48 juvenile rheumatoid arthritis 10.4 IL1B IL1RN IL2RA
49 brucellosis 10.4 IL1RN IL2RA IL4
50 obsessive-compulsive disorder 10.4

Graphical network of the top 20 diseases related to Somatoform Disorder:



Diseases related to Somatoform Disorder

Symptoms & Phenotypes for Somatoform Disorder

UMLS symptoms related to Somatoform Disorder:


dyspnea, headache, meningism, pain, reflex, abnormal, seizures, vertigo, multiple somatic complaints, neurobehavioral manifestations, labored breathing, neuromuscular manifestations, symptoms

MGI Mouse Phenotypes related to Somatoform Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.07 IL1B TRPA1 IL1RN TRPV1 IL2RA IL4
2 cardiovascular system MP:0005385 9.97 TPH1 IL1B IL1RN TRPV1 COMT NGF
3 immune system MP:0005387 9.9 IL1B TRPA1 IL1RN TRPV1 IL2RA IL4
4 integument MP:0010771 9.73 TRPA1 IL1RN TRPV1 IL4 NGF FAAH
5 nervous system MP:0003631 9.32 IL1B TRPA1 TRPV1 IL4 COMT NGF

Drugs & Therapeutics for Somatoform Disorder

Drugs for Somatoform Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 317)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Not Applicable 148553-50-8 5486971
2
Triamcinolone Approved, Vet_approved Phase 4,Phase 3 124-94-7 31307
3
Citalopram Approved Phase 4,Phase 3,Not Applicable 59729-33-8 2771
4
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
5
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 137-58-6 3676
6
Sertraline Approved Phase 4,Phase 3 79617-96-2 68617
7
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Early Phase 1 51-84-3 187
8 Piracetam Approved, Investigational Phase 4,Phase 3 7491-74-9
9
Acetaminophen Approved Phase 4 103-90-2 1983
10
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 54910-89-3 3386
11
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
12
Cycloserine Approved Phase 4,Early Phase 1 68-41-7 401 6234
13
Tibolone Approved, Investigational Phase 4 5630-53-5
14 Estradiol valerate Approved, Investigational, Vet_approved Phase 4 979-32-8
15
Gabapentin Approved, Investigational Phase 4,Phase 3,Not Applicable 60142-96-3 3446
16
Flunarizine Approved Phase 4 52468-60-7 941361
17
Histamine Approved, Investigational Phase 4,Phase 3 75614-87-8, 51-45-6 774
18
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
19
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
20
gamma-Aminobutyric acid Approved, Investigational Phase 4,Not Applicable 56-12-2 119
21
Polyestradiol phosphate Approved Phase 4 28014-46-2
22
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
23
Norepinephrine Approved Phase 4,Phase 3 51-41-2 439260
24 Mosapride Investigational Phase 4 112885-41-3
25 Etiracetam Investigational Phase 4,Phase 3 33996-58-6
26 triamcinolone acetonide Phase 4,Phase 3
27 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 calcium channel blockers Phase 4,Phase 3,Not Applicable
29 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
30 Cholinergic Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
31 Muscarinic Antagonists Phase 4,Phase 3,Not Applicable
32 Cholinergic Antagonists Phase 4,Phase 3,Not Applicable
33 Serotonin Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
34 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
35 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Anesthetics Phase 4,Phase 3,Phase 2,Not Applicable
38 Hormone Antagonists Phase 4,Phase 2
39 Anesthetics, Local Phase 4,Phase 3,Phase 2,Not Applicable
40 Tranquilizing Agents Phase 4,Phase 3,Not Applicable
41 Triamcinolone diacetate Phase 4,Phase 3
42 Triamcinolone hexacetonide Phase 4,Phase 3
43 Hormones Phase 4,Phase 2
44 Parasympatholytics Phase 4,Phase 3,Not Applicable
45 Anti-Anxiety Agents Phase 4,Phase 3,Not Applicable
46 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2
47 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1,Not Applicable
49 Anticonvulsants Phase 4,Phase 3,Phase 2,Not Applicable
50 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 261)
# Name Status NCT ID Phase Drugs
1 Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder Completed NCT00265109 Phase 4 Levetiracetam
2 Fluoxetine in Pediatric Body Dysmorphic Disorder Completed NCT00245635 Phase 4 Fluoxetine;Placebo
3 Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain Completed NCT02385266 Phase 4 D-Cycloserine;Placebo (for D-cycloserine)
4 Lansoprazole Versus Mosapride for Functional Dyspepsia Completed NCT00663897 Phase 4 lansoprazole;mosapride
5 Treatment of Myofascial Pain Syndrome With Lidocaine Injection and Physical Therapy. Completed NCT01250184 Phase 4 Lidocaine injection
6 Treatment Trial for Psychogenic Nonepileptic Seizures Completed NCT00835627 Phase 4 sertraline
7 Treatments for Psychogenic Nonepileptic Seizures (NES) Completed NCT00159965 Phase 4 sertraline;placebo
8 The Impact of Hormone Therapy on Lower Urinary Tract Symptoms, Sexual Function and Psychosomatic Disorder Recruiting NCT01822288 Phase 4 Tibolone;Estradiol & medroxyprogesterone acetate
9 GRASSP: Gralise® for Spine Surgery Pain Recruiting NCT01764464 Phase 4 Gralise®;Placebo
10 Neurologic Signatures of Chronic Pain Disorders Recruiting NCT02747940 Phase 4 flunarizine and/or pregabalin
11 CBT as an Adjunct to SRIs in the Treatment of BDD Terminated NCT00211809 Phase 4 Venlafaxine
12 Botox as a Treatment for Chronic Male Pelvic Pain Syndrome Terminated NCT00194623 Phase 4 Botulinum Toxin A (Botox)
13 Using Saline for Myofascial Pain Syndromes (USAMPS) Terminated NCT02120261 Phase 4
14 Chronic Bladder Pain Syndrome in Women: Can Doxycycline Help? A Prospective Study Terminated NCT01879930 Phase 4 doxycycline;placebo
15 Sinusitis and Facial Pain Disorders Anti-Depression Trial Terminated NCT00754793 Phase 4 escitalopram;placebo
16 Comparative Study of Epigastric Pain Syndrome and Postprandial Distress Syndrome Withdrawn NCT00673972 Phase 4
17 RCT :Thoracic Sympathetic Block for the Treatment of Complex Regional Pain Syndrome I of the Upper Limb Unknown status NCT01612364 Phase 3
18 Analysis of Photoplethysmographic Signal in Lumbar Sympathetic Block Unknown status NCT01134289 Phase 3
19 Intravenous Immunoglobulins in Complex-regional Pain Syndrome Unknown status NCT00949065 Phase 3
20 Efficacy & Safety Study of Pregabalin to Treat Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Unknown status NCT00371033 Phase 3 Pregabalin;Placebo
21 DEPENAS: A Psychosocial Intervention for Patients With Medically Unexplained Symptoms Completed NCT00130988 Phase 3
22 Treatment of Medically Unexplained Physical Ailments (Somatization Disorder) Completed NCT00050583 Phase 3
23 Comparing Cognitive Therapy and Exposure Therapy in Individuals With Hypochondriasis Completed NCT01119469 Phase 3
24 Integrated Treatment Program for Hypochondriasis in Primary Care Settings Completed NCT00368212 Phase 3
25 Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder Completed NCT00149799 Phase 3 Escitalopram;Placebo
26 Cytokine Inhibition in Chronic Fatigue Syndrome Patients Completed NCT02108210 Phase 2, Phase 3 Anakinra;Placebo
27 Treatment of Patients With Longstanding Unexplained Health Complaints Completed NCT00132197 Phase 2, Phase 3
28 Diacutaneous Fibrolysis and Patellofemoral Pain Syndrome Completed NCT02379364 Phase 3
29 Biofeedback-Based Cognitive Behavioral Treatment for Temporomandibular Disorders Completed NCT00769561 Phase 2, Phase 3
30 Pain Exposure Physical Therapy (PEPT) Versus CBO in Patients With Complex Regional Pain Syndrome Type I (CRPS-1) Completed NCT00817128 Phase 2, Phase 3
31 A Study of the Combination of Electrical Stimulation and Dysport® in Myofascial Pain Syndrome. Completed NCT00246142 Phase 3 Botulinum type A toxin (Dysport)
32 A Study of the Effect of Lenalidamide on Complex Regional Pain Syndrome Type 1 Completed NCT00166452 Phase 3 Lenalidamide
33 Efficacy Study of a Standardized Pollen Extract Preparation (Cernilton) to Treat Inflammatory Chronic Prostatitis-Chronic Pelvic Pain Syndrome (CP-CPPS) Completed NCT00919893 Phase 3 Cernilton;Placebo
34 A Confirmatory Study of Fentanyl in Participants With Post-herpetic Neuralgia, Complex Regional Pain Syndrome or Postoperative Pain Syndrome Completed NCT01008553 Phase 3 Fentanyl;Placebo
35 Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic Completed NCT01091662 Phase 3 Eslicarbazepine acetate 1600 mg;Eslicarbazepine acetate 1200 mg
36 Eslicarbazepine Acetate Monotherapy Long Term Study Completed NCT00910247 Phase 3 Eslicarbazepine acetate
37 Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome Recruiting NCT03184545 Phase 3
38 Efficacy and Safety of Intravenous Neridronic Acid in Complex Regional Pain Syndrome (CRPS) Recruiting NCT03560986 Phase 3 Neridronic acid;Placebo
39 Role of Vitamin C at 6 Months on Incidence of Complex Regional Pain Syndrome Type I in Upper Limb Surgery Recruiting NCT02390505 Phase 3 Vitamin C;Placebo
40 Treatment of Globus Sensations With Psychotherapy Active, not recruiting NCT01590992 Phase 2, Phase 3
41 Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome Active, not recruiting NCT02858453 Phase 3 AQX-1125 100 mg;AQX-1125 200 mg;Placebo
42 Efficacy Study of Bladder Instillation and Gabapentin on Interstitial Cystitis/Bladder Pain Syndrome. Not yet recruiting NCT03463915 Phase 3 Gabapentin Oral Capsule [Neurontin];Placebo Oral Capsule [CEBOCAP]
43 Botulinum Toxin Versus Placebo Injections to Temporalis and Masseter Muscles Not yet recruiting NCT03223298 Phase 3 Botulinum toxin type A;0.9% Sodium Chloride Injection
44 Pharmacovigilance in Gerontopsychiatric Patients Terminated NCT02374567 Phase 3 Phenobarbital;Phenytoin;Carbamazepine;Oxcarbazepine;Valproic Acid;Lamotrigine;Topiramate;Gabapentin;Levetiracetam;Pregabalin;Lacosamide;Clonazepam;Biperiden;Levomepromazine;Fluphenazine;Perphenazine;Perazine;Thioridazine;Haloperidol;Melperone;Pipamperone;Bromperidol;Benperidol;Sertindole;Ziprasidone;Flupentixol;Chlorprothixene;Zuclopenthixol;Fluspirilene;Pimozide;Clozapine;Olanzapine;Quetiapine;Sulpiride;Tiapride;Amisulpride;Prothipendyl;Risperidone;Aripiprazole;Paliperidone;Diazepam;Oxazepam;Lorazepam;Bromazepam;Clobazam;Alprazolam;Hydroxyzine;Buspirone;Chloral Hydrate;Flurazepam;Nitrazepam;Triazolam;Lormetazepam;Temazepam;Midazolam;Brotizolam;Zopiclone;Zolpidem;Zaleplon;Melatonin;Clomethiazole;Diphenhydramine;Promethazine;Imipramine;Clomipramine;Opipramol;Trimipramine;Amitriptyline;Nortriptyline;Doxepin;Maprotiline;Amitriptyline oxide;Fluoxetine;Citalopram;Paroxetine;Sertraline;Fluvoxamine;Escitalopram;Tranylcypromine;Moclobemide;Mianserin;Trazodone;Mirtazapine;Bupropion;Venlafaxine;Reboxetine;Duloxetine;Agomelatine;Pyritinol;Piracetam;Donepezil;Rivastigmine;Galantamine;Memantine;Nicergoline;Acamprosate;Lithium
45 Botulinum Toxin Type A for the Treatment of Male Chronic Pelvic Pain Syndrome Terminated NCT00464373 Phase 3 Botulinum Toxin Type A;Placebo
46 Study of Patients With Body Image Issues Treated With 2 Different Behavioral Interventions Unknown status NCT01316627 Phase 2
47 The Use of Zoledronic Acid to Complex Regional Pain Syndrome Unknown status NCT01788176 Phase 2 Zoledronic acid;Placebo
48 Effect of Delta-9-Tetrahydrocannabinol on the Prevention of Chronic Pain in Patients With Acute CRPS (ETIC-Study) Unknown status NCT00377468 Phase 2 Delta9-Tetrahydrocannabinol
49 Rehabilitation of Conversion Gait Disorder Unknown status NCT01422278 Phase 1, Phase 2
50 Cognitive Behavior Therapy for Somatization Disorder Completed NCT00276887 Phase 2

Search NIH Clinical Center for Somatoform Disorder

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Somatoform Disorder

Anatomical Context for Somatoform Disorder

MalaCards organs/tissues related to Somatoform Disorder:

41
Prostate, Brain, Cortex, Testes, Prefrontal Cortex, Spinal Cord, Bone

Publications for Somatoform Disorder

Articles related to Somatoform Disorder:

(show top 50) (show all 114)
# Title Authors Year
1
Somatoform disorder in primary care: The influence of co-morbidity with anxiety and depression on health care utilization. ( 29498165 )
2018
2
Stability of Cellular Immune Parameters over 12 Weeks in Patients with Major Depression or Somatoform Disorder and in Healthy Controls. ( 29895009 )
2018
3
Personalized treatment outcomes in patients with somatoform disorder: A concept mapping study. ( 29773148 )
2018
4
Complex regional pain syndrome type 1 in the medico-legal setting: High rates of somatoform disorders, opiate use and diagnostic uncertainty. ( 29865933 )
2018
5
The CIPRUS study, a nurse-led psychological treatment for patients with undifferentiated somatoform disorder in primary care: study protocol for a randomised controlled trial. ( 28468642 )
2017
6
Self-compassion in somatoform disorder. ( 29407566 )
2017
7
Somatoform disorder as a predictor of interstitial cystitis/bladder pain syndrome: Evidence from a nested case-control study and a retrospective cohort study. ( 28471951 )
2017
8
Depression and anxiety among patients with somatoform disorders, panic disorder, and other depressive/anxiety disorders in Taiwan. ( 27179181 )
2016
9
The Relationship of Hypochondriasis to Anxiety, Depressive, and Somatoform Disorders. ( 26785798 )
2016
10
Cognitive Alexithymia Mediates the Association Between Avoidant Attachment and Interpersonal Problems in Patients With Somatoform Disorder. ( 27185015 )
2016
11
Somatic symptom disorder and undifferentiated somatoform disorder, which is broader? Response to "Clinical value of DSM IV and DSM 5 criteria for diagnosing the most prevalent somatoform disorders in patients with medically unexplained physical symptoms (MUPS)". ( 27542553 )
2016
12
Dysaesthetic penoscrotodynia may be a somatoform disorder: results from a two-centre retrospective case series. ( 26932754 )
2016
13
Suicidality in patients with somatoform disorder - the speechless expression of anger? ( 27821358 )
2016
14
Harm avoidance and persistence are associated with somatoform disorder psychopathology: A study in Taiwan. ( 26919056 )
2016
15
Intensive multidisciplinary treatment of severe somatoform disorder: a prospective evaluation. ( 25594786 )
2015
16
The day-to-day concurrence of bodily complaints and affect in patients with severe somatoform disorder. ( 26032264 )
2015
17
Insecure attachment strategies are associated with cognitive alexithymia in patients with severe somatoform disorder. ( 26060261 )
2015
18
Relationship between alexithymia and coping strategies in patients with somatoform disorder. ( 24403835 )
2014
19
A comparative analysis of personality pathology profiles among patients with pure depressive-, pure anxiety-, and pure somatoform disorders. ( 25086291 )
2014
20
Fibromyalgia syndrome: a somatoform disorder? ( 24453056 )
2014
21
The spiral aftereffect technique (SAT) can differentiate between depressive and somatoform disorder patients. ( 24897884 )
2014
22
Is the DSM-5 chapter on somatic symptom disorder any better than DSM-IV somatoform disorder? ( 25029686 )
2014
23
Effectiveness of psychotherapy for severe somatoform disorder: meta-analysis. ( 24385460 )
2014
24
Effect of aripiprazole augmentation for treatment-resistant somatoform disorder: a case series. ( 24525655 )
2014
25
Psychotherapy for severe somatoform disorder: problems with missing studies. ( 24590981 )
2014
26
A sudden onset of a pseudo-neurological syndrome after HPV-16/18 AS04-adjuvated vaccine: might it be an autoimmune/inflammatory syndrome induced by adjuvants (ASIA) presenting as a somatoform disorder? ( 25388965 )
2014
27
Explanatory models of somatoform disorder patients attending a psychiatry outpatient clinic: A study from North India. ( 24029246 )
2013
28
Cognitive and affective dimensions of difficulties in emotional functioning in somatoform disorders and borderline personality disorder. ( 23006331 )
2013
29
Somatoform disorders in patients with chronic pain. ( 24288382 )
2013
30
Changes in brain activity of somatoform disorder patients during emotional empathy after multimodal psychodynamic psychotherapy. ( 23966922 )
2013
31
Prevalence, demographic and clinical characteristics of body dysmorphic disorder among psychiatric outpatients with mood, anxiety or somatoform disorders. ( 22029732 )
2012
32
Effect of tryptophan hydroxylase gene polymorphism on aggression in major depressive disorder and undifferentiated somatoform disorder. ( 22697203 )
2012
33
Rethinking the Psychogenic Model of Complex Regional Pain Syndrome: Somatoform Disorders and Complex Regional Pain Syndrome. ( 24223338 )
2012
34
Dysfunctional affect regulation in borderline personality disorder and in somatoform disorder. ( 22984638 )
2012
35
Combination of citalopram plus paliperidone is better than citalopram alone in the treatment of somatoform disorder: results of a 6-week randomized study. ( 22367417 )
2012
36
Relationship between neural activity and immunity in patients with undifferentiated somatoform disorder. ( 22801462 )
2012
37
Hypochondriasis, somatoform disorders, and anxiety disorders: sociodemographic variables, general psychopathology, and naturalistic treatment effects. ( 22551794 )
2012
38
Tactile perceptual processes and their relationship to somatoform disorders. ( 22149912 )
2012
39
Presentation of the Multidisciplinary Guideline Medically Unexplained Physical Symptoms (MUPS) and Somatoform Disorder in the Netherlands: disease management according to risk profiles. ( 22281461 )
2012
40
Altered brain activity during emotional empathy in somatoform disorder. ( 21998038 )
2012
41
Definition and structure of body-relatedness from the perspective of patients with severe somatoform disorder and their therapists. ( 22905144 )
2012
42
Validation of the PHQ-15 for somatoform disorder in the occupational health care setting. ( 21785907 )
2012
43
Gabapentin as add-on treatment for somatoform disorder: a case report. ( 22240859 )
2012
44
Somatoform disorder and the DSM-V Workgroup's interim proposals: two central issues. ( 22664310 )
2012
45
Public familiarity with the terms somatoform disorder and functional disorder in Germany: results from a representative population survey. ( 22690365 )
2012
46
Updates on Somatoform Disorders (SFMD) in Parkinson's Disease and Dementia with Lewy Bodies and discussion of phenomenology. ( 21813140 )
2011
47
Somatoform disorder after conscious sedation. ( 22136794 )
2011
48
A suspected case of somatoform disorder successfully treated with an herbal medicine. ( 21299430 )
2011
49
Serotonin-related gene pathways associated with undifferentiated somatoform disorder. ( 21531467 )
2011
50
Multimodal psychodynamic psychotherapy induces normalization of reward related activity in somatoform disorder. ( 21198419 )
2011

Variations for Somatoform Disorder

Expression for Somatoform Disorder

Search GEO for disease gene expression data for Somatoform Disorder.

Pathways for Somatoform Disorder

Pathways related to Somatoform Disorder according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.43 IL1A IL1B IL2RA IL4
2 12.34 COMT NGF OPRM1 SCN9A TPH1
3 12.28 CABIN1 IL1B IL1RN IL2RA IL4
4
Show member pathways
12.25 IL1A IL1B IL2RA IL4
5
Show member pathways
12.22 IL1A IL1B IL4 OPRM1
6
Show member pathways
11.84 IL1A IL1B IL2RA
7
Show member pathways
11.84 IL1A IL1B IL2RA IL4 NGF
8 11.81 IL1A IL1B IL4
9
Show member pathways
11.78 IL1B IL2RA IL4
10 11.61 IL1A IL1B IL4 OPRM1
11 11.57 IL1B IL2RA IL4
12
Show member pathways
11.53 CABIN1 IL2RA IL4
13 11.44 IL1A IL1B IL2RA IL4
14 11.31 IL1A IL1B IL1RN NGF TAC1 TPH1
15 10.97 IL1A IL1B IL4
16 10.95 IL1A IL1B IL1RN IL4
17
Show member pathways
10.92 COMT TPH1
18 10.3 IL1A IL1B

GO Terms for Somatoform Disorder

Cellular components related to Somatoform Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 8.92 COMT NGF OPRM1 TAC1

Biological processes related to Somatoform Disorder according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.91 IL1A IL1B IL1RN IL2RA IL4
2 cell surface receptor signaling pathway GO:0007166 9.86 CABIN1 IL2RA TRPA1 TRPV1
3 regulation of signaling receptor activity GO:0010469 9.85 IL1A IL1B IL1RN IL4 NGF
4 cytokine-mediated signaling pathway GO:0019221 9.8 IL1A IL1B IL1RN IL2RA IL4 OPRM1
5 inflammatory response GO:0006954 9.8 IL1A IL1B IL1RN IL2RA SCN9A TAC1
6 calcium ion transmembrane transport GO:0070588 9.77 OPRM1 TRPA1 TRPV1
7 response to lipopolysaccharide GO:0032496 9.77 COMT GCH1 IL1B OPRM1 TAC1
8 interleukin-1-mediated signaling pathway GO:0070498 9.74 IL1A IL1B IL1RN
9 positive regulation of T cell proliferation GO:0042102 9.65 IL1B IL2RA IL4
10 positive regulation of T cell differentiation GO:0045582 9.58 IL2RA IL4
11 inflammatory response to antigenic stimulus GO:0002437 9.58 IL1B IL2RA
12 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.55 IL1A IL1B
13 sensory perception of pain GO:0019233 9.55 OPRM1 SCN9A TAC1 TRPA1 TRPV1
14 positive regulation of monocyte chemotactic protein-1 production GO:0071639 9.54 IL1A IL1B
15 behavioral response to pain GO:0048266 9.52 SCN9A TRPV1
16 ectopic germ cell programmed cell death GO:0035234 9.49 IL1A IL1B
17 detection of chemical stimulus involved in sensory perception of pain GO:0050968 9.43 TRPA1 TRPV1
18 thermoception GO:0050955 9.4 TRPA1 TRPV1
19 fever generation GO:0001660 9.26 IL1A IL1B IL1RN TRPV1
20 response to pain GO:0048265 9.02 COMT GCH1 TAC1 TRPA1 TRPV1

Molecular functions related to Somatoform Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 IL1A IL1B IL1RN IL4
2 calcium-release channel activity GO:0015278 9.16 TRPA1 TRPV1
3 interleukin-1 receptor binding GO:0005149 8.8 IL1A IL1B IL1RN

Sources for Somatoform Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....